News
TFDA Approves SyneuRx's Schizophrenia Trials in Taiwan as part of its Global Schizophrenia Trials Press Release Mar 08, 2021 On March 8th, 2021, SyneuRx announced that the Taiwan FDA has…
Ω-NaBen, the Ultimate and Supreme Sodium Benzoate Press Release Jun 08, 2021 SyneuRx (TT6575) presents an important progress report in the “2021 Joint Spring Congress & Non-invasive Brain Stimulation Workshop”…
US FDA Approves SyneuRx’s IND Application for a First-in-Human, Proof of Principle Clinical Trial for Patients with Early and Mild COVID-19 Press Release Feb 04, 2021 SyneuRx announced today that…
SyneuRx’s SNS Patent Applications Have Been Granted in Taiwan and in the US. Press Release Sep 10, 2021 Taipei, September 10, 2018--SyneuRx announced today that its SNS patent applications, titled…
First Five Subjects Randomized in SyneuRx’ SND12 Phase IIb/III Study of Clozaben®, a Novel Treatment for Refractory Schizophrenia Press Release May 22, 2017 SyneuRx International (Taiwan) Corp. today announced that the…
First Three Subjects Randomized in SyneuRx’ SND13 Phase IIb/III NaBen© Schizophrenia Trial Press Release May 11, 2017 SyneuRx International (Taiwan) Corp. today announced that the first three subjects have been randomized…
FDA Approves SyneuRx’ IND Application for Late Phase Clinical Development of a Mild Dementia Treatment Press Release Apr 04, 2016 Germantown, MD, USA (April 4, 2016) - SyneuRx announced today,…
SyneuRx Receives US FDA Breakthrough Therapy Designation for SND12 for the Treatment of Refractory Schizophrenia in Adults Press Release Dec 19, 2015 Taipei, December 19, 2015- SyneuRx International (Taiwan) Corp.,…
